These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33169534)

  • 1. Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
    Hooimeyer A; Bhasale A; Perry L; Fabbri A; Mohammad A; McEwin E; Mintzes B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00680. PubMed ID: 33169534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
    Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab.
    Fabbri A; O'Keeffe M; Moynihan R; Møllebaek M; Mohammad A; Bhasale A; Puil L; Mintzes B
    Br J Clin Pharmacol; 2020 Jul; 86(7):1416-1429. PubMed ID: 32067255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States.
    Bhasale AL; Sarpatwari A; De Bruin ML; Lexchin J; Lopert R; Bahri P; Mintzes BJ
    Clin Pharmacol Ther; 2021 Jun; 109(6):1424-1442. PubMed ID: 32767557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do safety warnings on medicines affect prescribing?
    Mintzes B; Reynolds E; Bahri P; Perry LT; Bhasale AL; Morrow RL; Dormuth CR
    Expert Opin Drug Saf; 2022 Oct; 21(10):1269-1273. PubMed ID: 36208037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Decline of Direct General Practitioner Reporting of Adverse Drug Reactions in Australia and Paucity in Details of Australian Reports in Safety Advisories.
    Boyd IW; McEwen J
    Drug Saf; 2023 Jul; 46(7):703-710. PubMed ID: 37266905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS).
    Moore TJ; Morrow RL; Dormuth CR; Mintzes B
    Pharmaceut Med; 2020 Apr; 34(2):135-140. PubMed ID: 32180152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
    Kemp-Casey A; Mintzes B; Morrow RL; Dormuth CR; Souverein PC; Roughead EE
    Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1039-1045. PubMed ID: 35790047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance in Europe and North America: divergent approaches.
    Wiktorowicz M; Lexchin J; Moscou K
    Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis.
    Morrow RL; Mintzes B; Souverein PC; De Bruin ML; Roughead EE; Lexchin J; Kemp-Casey A; Puil L; Sketris I; Mangin D; Hallgreen CE; Pearson SA; Lopert R; Bero L; Ofori-Asenso R; Gnjidic D; Sarpatwari A; Perry LT; Dormuth CR
    BMJ Qual Saf; 2022 Mar; 31(3):179-190. PubMed ID: 35058332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
    Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N
    Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secret safety warnings on medicines: A case study of information access requests.
    Torka M; Mintzes B; Bhasale A; Fabbri A; Perry L; Lexchin J
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):551-555. PubMed ID: 30840349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.
    Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
    JAMA Intern Med; 2019 Jul; 179(7):982-984. PubMed ID: 31033999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of Canadian and U.S. approaches to drug regulation and responses to postmarket adverse drug reactions.
    Cheung RY; Goodwin SH
    J Diabetes Sci Technol; 2013 Mar; 7(2):313-20. PubMed ID: 23566987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.